Market Overview

Morgan Stanley Sees Growth Platforms Building for Stericycle

Share:
Related SRCL
Imperial Capital Initiates Stericycle With In-line
Benzinga's Top Initiations

In a report published Thursday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Stericycle (NASDAQ: SRCL).

In the report, Morgan Stanley noted, “Organic revenue growth in 4Q13 ticked up slightly versus 3Q13 but remains consistent with 2012-13 trends. Greater traction from StrongPak is a modest positive but drove margin dilution. Full valuation and limited visibility on sustainable growth acceleration keeps us from a more constructive view.”

Stericycle closed on Wednesday at $116.48.

Latest Ratings for SRCL

DateFirmActionFromTo
May 2015Stifel NicolausMaintainsBuy
Mar 2015Imperial CapitalInitiates Coverage onIn-line
Nov 2014Bank of AmericaMaintainsBuy

View More Analyst Ratings for SRCL
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (SRCL)

Around the Web, We're Loving...

Get Benzinga's Newsletters